Skip to main content
OpenTrials
Completed

NCT Number: NCT02517632

Physical Exercise Program in Chronic Chagas Heart Disease

The aim of this investigation is to evaluate the impact of exercise in a cardiac rehabilitation program on functional capacity, clinical markers, quality of life and biomarkers in patients with chronic chagasic cardiomyopathy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation.

Rio de Janeiro, 21040-360, Brazil

About this study

The present study consisted in a randomized clinical study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study are randomly divided in two groups: intervention and control groups. Safety analysis will be performed by monitoring any symptoms presented during data collection and follow-up study.

One of the potential risks that the patient may experience during the study is a noninvasive test that will be performed on a treadmill in a controlled environment, with the possibility of the appearance of symptoms such as fatigue, dyspnea, chest pain, dizziness, with minimal chances of occurring complications of difficult clinical control. Except for the blood test and the cardiopulmonary exercise test, the other tests to be performed are non-invasive and do not bring any risk to the participant's health. Will be collect 10 ml of blood which will be stored for up to five years for biomarker assessments.

During the exercise sessions, patients will be clinically monitored for decompensation, need for hospitalization and suspend or end the participation on the study. All cases will be individually assessed to determine the reversibility of the clinical status. Those cases will continue to be followed by the assistant staff, offering all the clinical support available in INI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(1) Chagas disease diagnosis by serology; (2) chronic chagasic cardiomyopathy, with left ventricular ejection fraction <45% or compensated heart failure (3) clinical stability in the last three months, (4) adherence to the ambulatory clinical treatment and (5) age above 18 years.

Exclusion criteria

(1) pregnancy, (2) neuromuscular limitations, (3) tobacco use, (4) evidence of nonchagasic heart disease, (5) systemic conditions that limits exercise practice or hemodynamic stress tests (6) unavailability to attend three times a week for a minimum of six months, (7) practitioners of regular exercise and (8) claustrophobia.

Treatment and study plan

Exercise, nutritional and pharmaceutical counceling

Behavioral

The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

Nutritional and pharmaceutical counceling

Behavioral

The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

Primary outcomes

  1. Functional capacity measured by peak exercise oxygen consumption

    Time frame: Changes from baselint at three and six months

    This measure is taken during a maximal progressive cardiopulmonary exercise test.

Secondary outcomes

  1. Muscle respiratory strength

    Time frame: Changes from baselint at three and six months

    Maximal inspiratory pressure and maximal expiratory pressure (cmH2O)

  2. Body composition (body fat percentage)

    Time frame: Changes from baselint at three and six months

    Measurement of skinfold thickness were taken at the chest, midaxillary, triceps, subscapular, abdomen, suprailiac and thigh sites on the right side of the body while standing in a relaxed position. The sum of these seven skinfold thicknesses was used to estimate body composition by Jackson & Pollock equation.

  3. Cardiac function (maily ejection fraction)

    Time frame: Changes from baselint at three and six months

    Meaured by echocardiography

  4. Laboratorial biomarkers composite

    Time frame: Changes from baselint at three and six months

    Total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol,triacylglycerol, glucose, glycated hemoglobin, inflammatory cytokines, Brain Natriuretic Peptide and components of oxidative stress.

  5. Quality of life

    Time frame: Changes from baselint at three and six months

    Minnesota Living with Heart Failure questionnaire (MLHFQ). Score ranging from 0 - 105.

  6. 24 hours Holter

    Time frame: Changes from baselint at three and six months

    Cardiac rhythm through continuous dynamic ECG

  7. Nutritional assessment

    Time frame: Changes from baselint at three and six months

    By semiquantitative food frequency questionnaire and 24-hour food intake recall.

  8. Pharmaceutical assessment

    Time frame: Changes from baselint at three and six months

    Semi-structured questionnaires, Morisky´s test, Naranjo Algorithm.

  9. Microvascular reactivity

    Time frame: Changes from baselint at three and six months

    Measured by laser speckle flowmetry

  10. Body mass index

    Time frame: Changes from baselint at three and six months

    Measured by the body weight (kg) divided by squared height (in meters).

Sponsors and collaborators

Lead sponsor

Evandro Chagas National Institute of Infectious Disease

Other

Collaborators

  • National Institute of Cardiology, Laranjeiras, Brazil

Registry information

Official study title

Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial)

Acronym: PEACH

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Aug 7, 2015
Registry last updated
Jul 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.